about
Signed, Sealed, Delivered: Microenvironmental Modulation of Extracellular Vesicle-Dependent Immunoregulation in the LungAntileukotriene agents for the treatment of lung diseaseLeukotrienes: underappreciated mediators of innate immune responsesStructural and functional criteria reveal a new nuclear import sequence on the 5-lipoxygenase proteinNuclear localization of leukotriene A4 hydrolase in type II alveolar epithelial cells in normal and fibrotic lungRap1 activation is required for Fc gamma receptor-dependent phagocytosisGuanylyl cyclase and protein kinase G mediate nitric oxide suppression of 5-lipoxygenase metabolism in rat alveolar macrophagesActivation of phosphatase and tensin homolog on chromosome 10 mediates the inhibition of FcgammaR phagocytosis by prostaglandin E2 in alveolar macrophagesLeukotrienes enhance the bactericidal activity of alveolar macrophages against Klebsiella pneumoniae through the activation of NADPH oxidaseBlocking macrophage leukotriene b4 prevents endothelial injury and reverses pulmonary hypertension.E-prostanoid 3 receptor deletion improves pulmonary host defense and protects mice from death in severe Streptococcus pneumoniae infectionTransient increase in cyclic AMP localized to macrophage phagosomes.Pivotal role of the 5-lipoxygenase pathway in lung injury after experimental sepsisPGE(2) inhibition of TGF-beta1-induced myofibroblast differentiation is Smad-independent but involves cell shape and adhesion-dependent signaling.Leukotriene B4 is a physiologically relevant endogenous peroxisome proliferator-activated receptor-alpha agonist.Prostaglandin E2 reduces Toll-like receptor 4 expression in alveolar macrophages by inhibition of translation.Lung fibroblasts from patients with idiopathic pulmonary fibrosis exhibit genome-wide differences in DNA methylation compared to fibroblasts from nonfibrotic lungArachidonic acid metabolism regulates Escherichia coli penetration of the blood-brain barrierHypermethylation of PTGER2 confers prostaglandin E2 resistance in fibrotic fibroblasts from humans and mice.Resident alveolar macrophages suppress, whereas recruited monocytes promote, allergic lung inflammation in murine models of asthmaLeukotriene B4 amplifies NF-κB activation in mouse macrophages by reducing SOCS1 inhibition of MyD88 expression.Clostridium difficile-induced colitis in mice is independent of leukotrienesRoles of cysteinyl leukotrienes in airway inflammation, smooth muscle function, and remodeling.Cysteinyl leukotriene interactions with other mediators and with glucocorticosteroids during airway inflammation.Extending the understanding of leukotrienes in asthma.Resident tissue-specific mesenchymal progenitor cells contribute to fibrogenesis in human lung allograftsDisruption of leptin receptor-STAT3 signaling enhances leukotriene production and pulmonary host defense against pneumococcal pneumonia.Leukotrienes and airway inflammationPlasmin overcomes resistance to prostaglandin E2 in fibrotic lung fibroblasts by reorganizing protein kinase A signalingAirway remodeling in murine asthma correlates with a defect in PGE2 synthesis by lung fibroblasts.Transcellular delivery of vesicular SOCS proteins from macrophages to epithelial cells blunts inflammatory signalingEvidence for tissue-resident mesenchymal stem cells in human adult lung from studies of transplanted allograftsProstaglandin E2 as an inhibitory modulator of fibrogenesis in human lung allograftsImpaired neonatal macrophage phagocytosis is not explained by overproduction of prostaglandin E2.The alveolar macrophage: the forgotten cell in asthma.Prostaglandin E(2) inhibits fibroblast migration by E-prostanoid 2 receptor-mediated increase in PTEN activityMacrophage dectin-1 expression is controlled by leukotriene B4 via a GM-CSF/PU.1 axis.Ablation of leptin receptor-mediated ERK activation impairs host defense against Gram-negative pneumonia.Prostaglandin E2 suppresses bacterial killing in alveolar macrophages by inhibiting NADPH oxidaseEicosanoids: mediators and therapeutic targets in fibrotic lung disease.
P50
Q28074704-203EA7B3-7E20-4539-BC77-898BB81A4FE0Q28293842-C463353B-802A-43BC-8B28-14B563B88F8CQ28301305-566C1050-C195-488D-863B-5769F1B95BFCQ28509450-E12AF57A-CEF4-4D21-B57C-4625F5348ED4Q28565050-B32390DF-7713-4759-BB1D-B2CDA10A5573Q28565336-B1C8BB54-99A9-44CF-9777-DCAB30402436Q28566790-6D10CFC1-E4E7-4183-9BA4-BA59F9F29D9CQ28572142-516AFD30-9EA1-4736-8AEE-C866D80B56AFQ28574027-9E250DD1-EBFB-4B80-A385-A703BFDA2EFDQ33593640-A52D5AF1-2503-476C-BD5F-F6D43FB738EBQ33594642-A3FDCCCE-F8DA-4B47-920E-5DD51818432AQ33749996-41627784-D85F-4531-BACE-2CC6595E4A74Q33756534-9FCE27C6-AC55-4E74-AE11-5F26F6786C07Q33756992-F837F9AF-D05C-4BBD-ABA9-0F80401CD3EEQ33991108-04560759-DBC9-4554-B2A7-B707A7CD48BFQ34103733-2FA54D38-715C-4A13-AB58-BDD3830DAD0FQ34172455-C38FB2D8-9392-450C-8412-A0781CACB1B6Q34177395-56F906A1-7EF5-4E89-A262-20D931457689Q34254378-07AD2343-800D-4A5C-AFA1-E192DF45C13BQ34289279-C165694F-14AC-4B28-B756-9AC0EE554AA9Q34519864-0AF40255-C99F-4C50-844F-9FEB851F5AF5Q34644107-97F2D29D-9CAF-4A2F-B755-771DADBFF340Q35047391-E30D0C9D-6B43-43B9-B722-2A885673EEADQ35047395-F16313E1-5F97-45E4-A8F4-A6E588CCF8BBQ35064801-AC369EB2-0865-40C5-B8DA-822233D5DB6EQ35070897-7F6EBA4B-292E-4A19-BF36-5CB2601AC0B7Q35096769-1AFA152B-62AF-46DB-8D3E-2C55FD18CB82Q35106124-A4441389-DF63-445D-BA88-F9D79532EDBDQ35213352-6C9B95E6-453D-4D23-A9F9-CC30EC3E75B4Q35543575-A39FD74A-229C-4C20-8206-A69576FA347FQ35568437-8962B4CF-0A8A-4A4A-AA76-10332BF1D13AQ35664090-5819C959-ADF4-4C77-B2D3-8D97AFC0B22AQ35683015-AAAE8821-B295-48D2-A54F-060342E70FC1Q35782203-A633862C-9ADF-4094-A62A-9AFEA0169240Q35811441-CFC70DC0-8DF9-470A-867B-4D0C4DBEBE24Q35973067-11DEF428-C702-43B1-B77F-1BEE0720396DQ36083704-6A04F79F-E0B1-4312-B380-B04E2E6B34CFQ36083988-B0602387-8628-4800-B4DE-C686FF2145BCQ36102855-AA9C00A4-BC9F-4030-9981-9F6A60297A12Q36128807-A363383E-AAE0-4041-A7D4-66CB4C6AB9F9
P50
name
Marc Peters-Golden
@en
type
label
Marc Peters-Golden
@en
prefLabel
Marc Peters-Golden
@en